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 Design—Secondary analyses of 2 international, randomized clinical trials (ACCESS 
[derivation cohort] and PROWESS-SHOCK [validation cohort]).
 Patients—Adults with severe sepsis admitted to the intensive care unit. We analyzed only 
patients who were functional and living at home without help before sepsis hospitalization 
(n=1,143 and 987 from ACCESS and PROWESS-SHOCK).
 Measurements and Main Results—In ACCESS and PROWESS-SHOCK, the average age 
of patients living at home independently was 63 and 61 years; 400 (34.9%) and 298 (30.2%) died 
by 6 months. In ACCESS, 580 patients had a QoL measured using EQ-5D at 6 months. Of these, 
41.6% could not live independently (22.7% were home but required help, 5.1% were in nursing 
home or rehabilitation facilities, and 5.3% were in acute care hospitals). Poor QoL at 6 months, as 
evidenced by problems in mobility, usual activities, and self-care domains were reported in 37.4%, 
43.7%, and 20.5%, respectively, and the high incidence of poor QoL was also seen in patients in 
PROWESS-SHOCK. Over 45%of patients with mobility and self-care problems at 6 months in 
ACCESS died or reported persistent problems at 1 year.
 Conclusions—Among individuals enrolled in a clinical trial who lived independently prior to 
severe sepsis, one third had died and of those who survived, a further one third had not returned to 
independent living by 6 months. Both mortality and QoL should be considered when designing 
new interventions and considering endpoints for sepsis trials.
 INTRODUCTION
Severe sepsis is defined as an infection associated with a systemic inflammatory response 
and acute organ dysfunction (1). It accounts for 10% of all intensive care unit (ICU) 
admissions, has a 90-day mortality of ~30% (2), and is the leading cause of death in US 
hospitals (3). Worldwide, best estimates suggest up to 19 million individuals develop severe 
sepsis each year (4).
Prior studies have shown that severe sepsis survivors incur long-term consequences, 
including developing new physical, psychiatric and cognitive deficits (5–7). These deficits 
often limit their mobility and ability to perform day-to-day activities and may impair quality 
of life (8). As a greater proportion of patients survive hospitalization for severe sepsis, the 
population that is at risk for these long-term consequences will increase (9).
We sought to determine long-term quality of life among severe sepsis survivors. We 
addressed 2 key limitations of prior studies. First, prior studies compared quality of life 
among severe sepsis survivors to age-matched population-based controls (8). However, 
patients with sepsis often have a high burden of chronic diseases or functional limitations 
before developing sepsis, and thus long-term impairments in quality of life may be due to 
sepsis itself or poor health before onset of sepsis. Second, these studies had a small sample 
size and included patients from a single geographic region. We assessed the quality of life in 
severe sepsis survivors enrolled in 2 large international clinical trials. We determined the 
quality of life at 6 months in patients who were functional and self-sufficient before the 
onset of sepsis. We conducted sensitivity analyses in young patients and those who did not 
have a chronic disease to assess the independent effect of sepsis on quality of life. Finally, 
we also examined the predictors of poor quality of life among survivors, particularly 
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whether it is affected by the severity and type of organ dysfunction during the acute sepsis 
episode.
 MATERIALS AND METHODS
We conducted a secondary analysis of patients enrolled in 2 clinical trials: A Controlled 
Comparison of Eritoran and placebo in patients with Severe Sepsis (ACCESS, n=1,984) and 
PROWESS SHOCK (n=1,697). Details of these trials are published elsewhere (10, 11). The 
ACCESS and PROWESS-SHOCK trials tested the efficacy of Eritoran, a MD2:toll-like 
receptor 4 antagonist, and Drotrecogin alfa activated (recombinant human activated Protein 
C), an anticoagulant and profibrinolytic enzyme, against placebo. In both trials there was no 
difference in survival in patients who were assigned to receive the active agent or the 
placebo. We conducted primary and sensitivity analyses and analyzed predictors of reduced 
quality of life (see Statistical Analysis section) in ACCESS and validated the results of the 
primary analyses in PROWESS-SHOCK trial.
To minimize the potential effect of pre-existing functional impairment, we restricted analysis 
in both trials to subjects who were functional and living at home without help prior to 
hospitalization for severe sepsis (see Online Supplement). All subjects or their legal 
surrogate gave informed consent and the Institutional Review Board at each site approved 
the study.
 Patients
The ACCESS trial enrolled patients who were at least 18 years old with early severe sepsis 
or septic shock and high risk of death. Severe sepsis was defined as documented evidence of 
infection, at least 3 criteria for systemic inflammatory response syndrome (SIRS), and at 
least 1 major organ dysfunction. Septic shock was defined as hypotension requiring 
vasopressors. High risk of death was defined as having an Acute Physiology and Chronic 
Health Evaluation (APACHE) II score of at least 21 and not greater than 37. The 
PROWESS-SHOCK trial used similar entry criteria, except included only patients with 
persistent septic shock and had no enrollment restriction based on APACHE II score. Both 
trials included patients from North and South America, Europe, Africa, Asia, and Australia. 
In general, the exclusion criteria were similar and excluded patients who did not want to 
pursue aggressive care (see Online Supplement).
 Quality of Life
The primary outcome variable was quality of life, assessed over 1 year in ACCESS and 6 
months in PROWESS-SHOCK. Quality of life was assessed using a previously validated 
instrument, EQ-5D (http://www.euroqol.org/home.html). It was chosen for both trials 
because it has been used in patients with sepsis previously (12, 13), it can be completed in a 
few minutes, and it is available in several languages. The EQ-5D measures the health state in 
5 domains: mobility, self-care, usual activities, pain or discomfort, and anxiety or 
depression. Each domain can take 1 of 3 responses: no problems, some or moderate 
problems, and extreme problems.
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The EQ-5D was obtained by telephone interview either from the patient or proxy. The time 
window to obtain measures at 6 months was between month 5 and 7 and at 1 year was 
between month 11 and 13 after enrollment in the original trial.
 Statistical Analysis
We report the clinical characteristics of the subjects prior to and at enrollment and their 
hospital course in both trials. In the ACCESS cohort, we conducted primary and sensitivity 
analyses and analyzed patterns of changes in select quality of life measures (mobility and 
self-care) between 6 months and 1 year, and identified predictors of quality of life at 6 
months. We validated the primary analyses in PROWESS-SHOCK.
For the primary analyses, we determined where patients were located (home, acute care 
hospitals, nursing home, or rehabilitation facilities), whether they needed assistance, and 
quality of life measures (frequency of patients who had problems with mobility, self-care, 
and usual activities and who reported pain or discomfort and anxiety or depression).
Patients hospitalized with severe sepsis are often older adults and have chronic diseases, thus 
they may have reduced quality of life prior to sepsis. We therefore conducted 2 sensitivity 
analyses in young patients (<45 years) and those who did not have a chronic disease to 
reduce likelihood of confounding due to these factors. We conducted these sensitivity 
analyses in the ACCESS cohort and defined a chronic disease as those individuals who 
reported cardiovascular, kidney, lung, connective tissue diseases, heart failure, diabetes, 
cancer, AIDS, dementia, and stroke.
We report patterns of changes in mobility and self-care between 6 months and 1 year in the 
ACCESS trial. We chose these outcomes because impairments in these domains were 
common and these impairments are likely to affect the patient’s functional status. We 
identified patients with problems in these domains at 6 months and the proportion that had 
persistent problems (reported some, moderate, or extreme problem), recovered completely 
(reported no problem), and died.
Finally, we used logistic regression to determine factors prior to and during the acute 
episode that were associated with poor quality of life in the ACCESS cohort. We constructed 
2 models to predict problems with mobility and self-care at 6 months. For each model, 
covariates included demographic characteristics, chronic disease burden (defined as presence 
or absence of a chronic disease), and duration of organ failure within the first 28 days, 
including mechanical ventilation, dialysis, and vasopressor support, as a proxy for the 
duration and severity of organ failure. We split each organ support variable into individuals 
who did and did not require the organ support, and among the later, we calculated the odds 
ratios for increase in organ support in increments of 7 or 14 days. We did not use daily 
sequential organ failure scores because these data were collected only on select days and 
require imputation. All analyses were done using SPSS 21 or SAS 9.4.
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 RESULTS
 Patient characteristics
Of the 1,984 and 1,697 patients enrolled in ACCESS and PROWESS-SHOCK, 1,143 
(57.6%) and 987 (58.1%) patients were fully functional and living at home without help 
prior to hospitalization with severe sepsis (Figure 1).
For patients in the ACCESS cohort (derivation cohort) and included in this analysis, the 
mean age was 63.2 years and 454 (39.7%) were women (Table 1). Five hundred and eighty 
six (51.3%), 340 (29.7%), and 80 (7.0%), 73 (6.4%), 64 (5.6%) were from Europe, North 
America, Asia, South America, and rest of the world, respectively. Three hundred and forty 
seven (30.3%), 254 (14.0%), 235 (13.4%), 161 (8.9%), 142 (7.8%), and 58 (3.2%) had 
diabetes, pulmonary disease, cancer, kidney disease, ischemic heart disease, and heart 
failure, respectively. Eight hundred and twenty seven patients (72.4%) had at least one or 
more chronic disease. At enrollment, the illness severity was high (1,269 [64%] had an 
APACHE II score of 25 or higher and 397 [34.7%], 273 [23.9], and 111 [9.7%] had 
dysfunction in 2, 3, and 4 or more organ systems, respectively).
In general, the demographic characteristics, chronic disease burden, and illness severity of 
patients analyzed from the PROWESS-SHOCK cohort (validation cohort) were similar to 
those analyzed from the ACCESS trial (Table 1). Additional details are provided in the 
Online Supplement (Section IV).
 Mortality
In the ACCESS trial, 289 (25.3%), 363 (31.8%), and 400 (34.9%) patients died at 28 and 90 
days and at 6 months, respectively. In the PROWESS-SHOCK trial, 202 (20.5%), 273 
(27.7%), and 298 (30.2%) patients died at the same time points, respectively.
 Quality of life
At 6 months, of the 1,143 patients in the ACCESS trial, 626 (54.7%), 400 (34.9%), and 117 
(10.2%) were alive, dead, and lost to follow-up, respectively (Table 1). A quality of life 
measure was obtained in 580 patients (78%, 580 of the 743 patients who had not died by 6 
months, Figure 1). Of these, 58.4% were home and fully functional, 22.7% were home but 
required help, 5.1% were in nursing home or rehabilitation facilities, and 5.3% were in acute 
care hospitals (living status was not known for 8.5% patients).
At 1-year, 467 (40.8%), 424 (37.2%), and 252 (22%) were alive, dead, and lost to follow-up, 
respectively (Table 1). A quality of life measure was obtained for 448 patients (62.3%, 448 
of the 719 patients who had not died by 1 year). Of these, 69% of the survivors were at home 
and fully functional, 17% were at home but required help, 3.1% were in nursing home or 
rehabilitation facilities, and 3.1% were in acute care hospitals (living status was not known 
or 7.8% patients).
A large proportion of patients reported a problem with mobility, usual activities, and self-
care over 1 year. Of the 580 survivors with an EQ-5D measure at 6 months, more than a 
third reported problems with mobility (218 patients, 37.5%) and usual activities (254 
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patients, 43.7%) and 119 (20.5%) patients reported problems performing self-care. Of the 
580 responses, 496 (85.5%) were obtained from the patients and proxies reported 84 
(14.5%) responses. The proxies included spouse or significant other (36.9%), child (26.2%), 
parent (7.1%), sibling (3.6%), friends (1.2%), other family members (9.5%), paid caregiver 
(13.1%), and others (2.4%).
Among the 448 survivors with a quality of life at 1 year, 142 (31.7%), 145 (32.3%), and 66 
(14.7%) reported problems with mobility, usual activities, and self-care activities, 
respectively. A large proportion of patients also reported pain or discomfort and anxiety or 
depression at 1 year (41.4% and 35.2% reported pain or discomfort; 29.4% and 25% 
reported anxiety or depression by 6 and 12 months, respectively). Of the 448 responses, 388 
(86.6%) were obtained from the patients, proxies reported 52 (11.6 %) responses, and data 
were missing in an additional 8 (1.8%) patients. The proxies included spouse or significant 
others (42.3%), child (30.8%), parent (5.8%), sibling (7.7%), friends (1.9%), other family 
members (3.8%), and paid caregiver (5.8%).
Long-term follow-up was limited to 6 months in the PROWESS-SHOCK trial. At 6 months, 
of the 987 patients, 580 (58.8%), 298 (30.2%), and 109 (11%) were alive, dead, and lost to 
follow-up, respectively (Table 1). At 6 months, the findings were similar to ACCESS; 61% 
were home and fully functional, 26.6% were home but required help, 4.1% were in a nursing 
home or rehabilitation facilities, and 3.6% were in acute care hospitals. The EQ-5D data 
were available for 580 survivors at 6 months. Of these, 211 (36.4%) patients reported 
problems with mobility, 242 (41.7%) with performing usual activities, and 119 (20.5%) 
reported problems performing self-care. Two hundred and seventy six (47.7%) patients 
reported pain or discomfort and 205 (35.5%) reported anxiety or depression.
 Sensitivity analyses
In the ACCESS cohort, the proportion of patients who reported a problem with mobility, 
usual activities, and self-care were similar among those with and without a chronic disease 
(Figure 2). The proportion of patients who reported some problem with mobility and self-
care was lower among those <45 years (17.9% and 7.7%), but a third (30.8%)were unable to 
return to usual activities by 6 months.
 Patterns of quality of life between 6 months and 1 year
Of the 218 patients in the ACCESS cohort who reported problem with mobility at 6 months, 
105 (48.1%) reported persistent problem with mobility, 15 (6.8%) survivors had died, and 45 
(20.6%) patients reported no problems with mobility by 1 year (status of an additional 53 
patients was unknown). Similarly, of the 119 patients who reported some problem with self-
care at 6 months, 42 (35.3%) survivors reported a persistent problem with self-care, 12 
(10.1%) had died, and 36 patients report no problems with self-care by 1 year (status of an 
additional 29 patients was unknown). Thus, most patients who reported problems with 
mobility or self-care at 6 months had poor subsequent outcomes.
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 Predictors of impaired quality of life
Table 2 shows predictors of problems with mobility and self-care at 6 months in the 
ACCESS cohort; age was an important predictor, but the presence of chronic disease before 
sepsis was not. Treatment with mechanical ventilation or dialysis for 14 or more days was 
associated with problems with mobility and self-care, but the duration of vasopressor 
support was not an important predictor.
 DISCUSSION
Two large international trials independently studying separate treatments for severe sepsis 
revealed strikingly similar findings. Approximately one third of patients who were 
functionally independent and residing at home before the onset of sepsis had died by 6 
months and a third of the survivors reported problems with mobility and performing self-
care or usual activities. Most patients were unable to live at home independently and either 
required assistance at home, or resided in nursing home or rehabilitation facilities, or they 
were in acute care hospitals. Furthermore in the ACCESS cohort, half of these patients either 
died or did not improve by 1 year. The poor quality of life in survivors is less likely to be 
attributed to advanced age or high burden of chronic diseases, and likely due to persistent 
critical illness and prolonged treatment with mechanical ventilation or dialysis.
Our findings are consistent with prior studies and have important implications (5, 6, 8). First, 
there is a need to identify strategies during the hospital course, such as early rehabilitation, 
or after hospital discharge, such as follow-up clinics (7), to improve quality of life for severe 
sepsis survivors. Second, currently US Food and Drug Administration recommends using 
28-day all-cause mortality as a primary endpoint for sepsis trials. However, using mortality 
alone would ignore functional impairments that occur among sepsis survivors and affect 
quality of life. Future sepsis trials should consider a composite endpoint that incorporates 
mortality and either quality of life or disability measures. These measures are patient-
centered outcomes and they are likely to increase caregiver burden. Our findings suggest that 
quality of life or disability measures obtained at 6 months may be adequate rather than 
waiting longer because half of patients who reported problems with mobility or self-care 
either died or did not improve subsequently. Third, consistent with prior studies, our findings 
showing that a third of sepsis survivors need assistance demonstrate the high societal costs 
of caring for sepsis survivors. As the incidence of sepsis increases and the short-term 
mortality decreases, cost of caring for sepsis survivors will likely increase over time.
Our study has several strengths. First, our findings of similar long term outcomes in 2 large, 
contemporary cohorts strength the inferences that can be drawn from our data. Second, 
patients were enrolled from various countries, thus our results may be considered widely 
generalizable. Third, our primary analysis was restricted to those who were functional and 
living independently prior to hospitalization with severe sepsis and we also conducted 
sensitivity analysis in young adults and those without chronic diseases; we thus sought to 
minimize confounding due to advanced age or pre-existing chronic disease. That our 
findings were similar in the primary and sensitivity analyses, suggests that we succeeded in 
minimizing such confounding.
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Our study has limitations. Although EQ-5D has been widely used, it has not been validated 
for patients recovering from sepsis. In particular, EQ-5D may not be accurate in individuals 
with cognitive impairments (14). We also did not calculate quality-adjusted life years 
because each health state is assigned a value set based on the country of origin and this value 
set is not available for participants from several countries included in our study. Although 
we limited our analysis to patients who were living at home without help, quality of life was 
not available before onset of severe sepsis hospitalization. Thus, we may have overestimated 
the impairment in quality of life due to severe sepsis. We also did not collect quality of life 
measures using visual analog scale (EQ-VAS). Finally, data were missing for some patients. 
Often, these data are missing for those with worse values and we may have underestimated 
the frequency of some limitations.
 CONCLUSION
Approximately one third of patients who survived hospitalization for severe sepsis had died 
at 6 months. Another third experienced problems with mobility and self-care and were not 
able to live independently at this time point. Half of the survivors who had these problems at 
6 months had either died by 1 year or had persistent problems. In addition to mortality, 
future studies should consider persistent functional impairment as an outcome measure and 
examine strategies to improve both longevity and quality of life in patients who survive 
severe sepsis.
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Figure 1. 
Flow chart describing selection of analyses cohorts and number of patients with quality of 
life measures
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Figure 2. 
Proportion of patients who reported problems with mobility, self-care, and usual activities 
for all patients (panel A) who were functional prior to onset of severe sepsis and in the 
subsets that were young (<45 years old, panel B) and without chronic diseases (panel C).
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Table 1
Clinical characteristics of sepsis survivors who were fully functional prior to hospitalization
Variable ACCESS cohort (n=1143) PROWESS-SHOCK cohort (n=987)
Demographics
 Age, mean (SD) y 63.2 (14.6) 61.6 (15.7)
 Women, No. (%) 454 (39.7) 414 (41.9)
 Race, No. (%)
  White 958 (83.8) 852 (86.3)
  Black 55 (4.8) 32 (3.2)
  Asian/non-Japanese 29 (2.5) 59 (6.0)
  Japanese 71 (6.2) 0 (0)
  Others 30 (2.6) 44 (4.5)
Region, No. (%)
 Europe 586 (51.3) 742 (75.2)
 North America 340 (29.7) 121 (12.3)
 South America 73 (6.4) 34 (3.4)
 Asia 80 (7.0) 90 (9.1)
 Rest of the world 64 (5.6) 0 (0)
Chronic diseases, No. (%)a
 Diabetes 347 (30.3) 225 (22.8)
 Chronic pulmonary disease 254 (14.0) 143 (14.7)
 Cancer 235 (13.4) 173 (17.5)
 Moderate or severe renal disease 161 (8.9) 72 (7.3)
 Ischemic heart disease 142 (7.8) 97(9.8)
 Heart failure 129 (7.1) 36 (3.6)
 Stroke or transient ischemic attack 85 (4.7) 39 (4.0)
 Moderate or severe liver disease 58 (3.2) 37 (3.7)
Infection sitea, No. (%)
 Lung 571 (44.1) 468 (47.4)
 Genitourinary 189 (25.2) 98 (9.9)
 Abdomen 268 (20.7) 319 (32.3)
 Skin/soft tissue 95 (7.3) 69 (7.0)
 Primary blood stream 37 (2.9) 163 (16.5)
 Catheter-related bacteremia 24 (1.9) -
 Central nervous system 40 (3.1) 15 (1.5)
 Other 70 (5.4) 34 (3.4)
Illness severity
 APACHE II score, Mean (SD) 26.8 (4.3) 24.8 (8.0)
 With organ dysfunctions, No. (%)
  1 362 (31.7) 15 (1.5)
  2 397 (34.7) 122 (12.4)
  3 273 (23.9) 326 (33.0)
Crit Care Med. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Yende et al. Page 13
Variable ACCESS cohort (n=1143) PROWESS-SHOCK cohort (n=987)
  4 98 (8.6) 385 (39.0)
  5 13 (1.1) 139 (14.1)
Type of organ dysfunctionsa, No. (%)
 Acute lung injury/ARDS 116 (10.1) 773 (78.3)
 Thrombocytopenia 95 (8.3) 248 (25.1)
 Lactic acidosis 291 (25.5) 460 (47.1)
 Shock 551 (48.2) 987 (100)
 Acute kidney injury 90 (7.9) 746 (75.6)
Duration of organ support
 Mechanical ventilation, Median (IQR) 7 (2, 15) 6 (2, 15)
 Dialysis, Median (IQR) 0 (0, 2) 0 (0, 3)
 Vasopressor use, Median (IQR) 3 (2, 7) 4 (2, 7)
Length of stay
 ICU, Median (IQR) 11 (6, 22) 11 (6, 21)
 Hospital, Median (IQR) 21(10, 28) 22 (12, 29)
Mortality, No. (%)
 6-month mortality
  Alive 626 (54.7) 580 (58.8)
  Dead 400 (34.9) 298 (30.2)
  Missing 117 (10.2) 109 (11)
 1-year mortalityb
  Alive 467 (40.8) -
  Dead 424 (37.2) -
  Missing 252 (22) -
aNumbers don’t add up to 100% because patients may be part of more than 1 category;
b1-yr mortality not available for PROWESS-SHOCK cohort
APACHE – Acute Physiology and Chronic Health Evaluation score; ARDS – acute respiratory distress syndrome; ICU – intensive care unit; IQR - 
Interquartile range
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